Search Bar & Filters
Found 23 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying patients with cirrhosis caused by alcohol-related or metabolic dysfunction-associated steatotic liver disease MASLD. The trial aims to evaluate whether taking capsules containing faecal microbiota from healthy donors can reduce infections and mortality in these patients. This Phase 3 trial follows earlier research that showed faecal microbiota transplantation FMT delivered via endoscopy was safe and feasible, leading to the development of capsules for easier treatment administration. Participants will be randomly assigned to receive either encapsulated FMT or placebo capsules that look identical but contain no active treatment. They will take five capsules every three months over a total period of 21 months or until they develop an infection requiring hospital admission. This double-blind trial means neither participants nor study staff will know which treatment is given. The study will last up to 24 months including follow-up, monitoring effects on infection rates, liver health, immune system function, and antibiotic resistance. Throughout the trial, participants will be regularly assessed for infections, liver disease progression, hospital admissions, quality of life, mental health, alcohol use, and safety of FMT treatment. Laboratory tests will examine immune response and bacterial resistance. The primary outcome is the time until first infection needing hospital care. The study involves detailed monitoring and follow-up visits for up to two years to understand the treatments impact and safety in patients with cirrhosis.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.
Actively Recruiting
This research aims to evaluate whether using Bioimpedance Analysis BIA can improve fluid management in patients hospitalized with worsening heart failure. The study compares BIA-guided treatment to standard care to see if this approach reduces the need for extra diuretic treatment or rehospitalization within 90 days after discharge. Heart failure affects millions worldwide, and managing fluid levels accurately is a key challenge in preventing hospital readmissions and worsening symptoms. Participants will be randomly assigned to one of two groups. The BIA-guided group will have BIA measurements performed within 24 hours of admission and throughout their hospital stay to guide fluid management and diuretic use. The standard care group will also have BIA measurements at admission and discharge, but these results will not be shared with their care team, who will manage fluid levels based on usual clinical assessments. After discharge, all patients will attend a follow-up visit 2 to 4 weeks later for health checks, blood tests including NT-proBNP, and a quality-of-life questionnaire. During the study, participants will undergo standard clinical exams, blood tests, and questionnaires to assess heart failure symptoms and quality of life. Researchers will track hospital readmissions, need for additional treatment, kidney function, length of hospital stay, and mortality up to 12 months after discharge. The main outcome is the rate of heart failure events within 90 days post discharge. Safety and long-term effects will also be monitored, with data analyzed after all participants have completed follow-up.
Actively Recruiting
Researchers are conducting a multi-centre observational study to better understand giant cell arteritis GCA and polymyalgia rheumatica PMR, conditions mainly affecting people over 50 years old. The study aims to identify genetic factors that influence susceptibility to these diseases to provide new insights into how they develop. It includes both retrospective participants with confirmed diagnoses and prospective participants suspected of having these conditions, with some patients also enrolled in a registry monitoring tocilizumab treatment for relapsing or refractory GCA. The study collects detailed clinical, imaging, and molecular data, including genetic and proteomic analyses, from participants to characterize disease subtypes and impacts. Researchers also assess quality of life through patient-reported outcomes and track long-term prognosis by linking to health records. The study explores environmental factors and co-existing conditions to improve diagnosis, prognosis, and monitoring of disease activity, especially for patients receiving synthetic or biological disease-modifying anti-rheumatic drugs. Participants provide information during baseline assessments, including blood and urine samples for analysis, and complete questionnaires about their symptoms and quality of life. Follow-up occurs through health record review over an average of one year to evaluate diagnosis and disease outcomes. The primary measure is genetic susceptibility, with secondary outcomes focusing on disease characteristics, life impact, diagnosis, and disease activity. The study is sponsored by the University of Leeds and started in 2005, continuing through 2028.
Actively Recruiting
Researchers are evaluating the safety and performance of remote monitoring functions in ALIZEA, BOREA, and CELEA pacemakers for patients with bradycardia. This observational clinical investigation focuses on the devices Right Atrial Autothreshold RAAT, Right Ventricular Autothreshold RVAT, and remote alert features. The study aims to document these functions over time to better understand their reliability and safety. Participants will be included soon after pacemaker implantation and followed for 48 months. Follow-up visits occur both on-site and remotely at 1 to 3 months, 6 months, 12 months, 24 months, and 48 months after inclusion. During these visits, the remote monitoring functions and the pacing systems performance will be measured, and safety will be continuously monitored throughout the study. Throughout the study, researchers will assess cardiac pacing thresholds, technical remote alerts, and the usability of the pacemaker and remote monitoring systems. Evaluations include Right Atrial and Right Ventricular pacing thresholds at multiple timepoints up to 48 months. Participants will undergo scheduled check-ins involving measurements, monitoring, and safety assessments, with the total study duration lasting four years after enrollment.
Actively Recruiting
Atrial fibrillation AF is a common irregular heart rhythm that contributes to heart failure HF. Researchers are evaluating whether catheter ablation combined with optimal medical therapy can reduce hospitalizations due to heart failure and death compared to medical therapy alone. This international, randomized trial focuses on patients with HF and reduced heart function who have paroxysmal or persistent AF, aiming to clarify if ablation improves survival and quality of life beyond current treatments. Participants will be randomly assigned to either optimal medical therapy following European Society of Cardiology guidelines or to catheter ablation plus optimal medical therapy. The ablation procedure involves pulmonary vein isolation using techniques such as cryoballoon, radiofrequency, or pulsed field ablation, chosen by the treating physician. Additional ablation lesions may be applied as needed. This open-label multicenter trial plans to recruit 1200 patients and is nearly three times larger than previous studies in this area. During the study, participants will be monitored for a minimum of two years, with follow-up extending up to 5.5 years. The main outcome measured is the time to first all-cause death or urgent cardiovascular hospitalization. Secondary outcomes include repeated hospitalizations, quality of life assessed at six and twelve months, and cardiovascular death rates. Researchers will collect electro-anatomical voltage maps during ablation for further analysis, while patients will be regularly assessed for heart function, symptoms, and quality of life through clinical visits and questionnaires.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Shockwave Reducer device for patients with refractory angina pectoris who have persistent chest pain despite maximum medical therapy and are unsuitable for revascularization. This study includes a randomized, double-blind, sham-controlled trial comparing the Shockwave Reducer implant to a placebo procedure, as well as a non-randomized registry for special patient groups such as those with right coronary artery ischemia, abnormal coronary flow reserve, or mobility impairments preventing exercise testing. Participants in the randomized trial are assigned to receive either the Shockwave Reducer implant or a sham procedure with no device implanted. The registry group includes patients treated with the Shockwave Reducer who do not meet randomization criteria. The study involves implantation procedures, with evaluations of heart function and ischemia before enrollment. The trial spans multiple centers and uses a parallel study design. During the study, participants will undergo assessments including exercise tolerance tests, coronary angiography, and imaging to measure ischemia and heart function. Researchers will monitor angina symptoms using the Canadian Cardiovascular Society Angina Score and evaluate safety and effectiveness at six months. Participants are followed up for adherence to therapy and clinical status. The total study duration extends up to the primary completion date in July 2027, with ongoing long-term monitoring until 2032.
Actively Recruiting
Researchers are evaluating the Shockwave Intravascular Lithotripsy IVL System with the Shockwave Javelin Coronary IVL Catheter to treat calcified, narrowed coronary artery lesions before stenting. This prospective, multicenter, single-arm investigational device exemption study aims to assess the safety and performance of this device in patients with moderate to severely calcified coronary artery disease, including those with stable angina or after stabilization from acute coronary syndrome. The study uses the Shockwave Javelin Coronary IVL Catheter, designed to deliver intravascular lithotripsy to modify calcium in tight, difficult-to-cross lesions. This treatment aims to increase vessel compliance, allowing better device crossing and additional therapies as needed. Up to 158 subjects will be enrolled initially, followed by an extended cohort of up to 250 additional participants, all undergoing non-emergent percutaneous coronary intervention using the device. Participants will be monitored with assessments including freedom from major cardiac events within 30 days and technical success of the procedure during the intervention. The study involves screening, treatment with the investigational device, and follow-up visits to evaluate safety and effectiveness. Researchers will collect clinical data including biomarkers, heart function measurements, and angiographic imaging to assess outcomes throughout the study period.
Actively Recruiting
This research investigates whether personalized medical treatment guided by a special diagnostic procedure during invasive coronary angiography can improve symptoms, wellbeing, cardiovascular risk, and clinical outcomes in patients with angina but no significant blockage in their coronary arteries. It focuses on patients with ischaemic heart disease, particularly those with angina without obstructive coronary artery disease INOCA, a condition affecting the small vessels of the heart. The trial builds on earlier pilot studies that suggested this approach could improve quality of life and symptom control by tailoring diagnosis and treatment more precisely. Participants undergo functional coronary angiography with a guidewire-based interventional diagnostic procedure IDP that measures coronary vascular function to classify patients into specific diagnosis groups, such as microvascular or vasospastic angina. Eligible patients are randomized into two groups one where IDP results are disclosed to clinicians to guide treatment, and another where IDP is performed but results are hidden, with care based on standard angiography and clinical information. Both groups receive medical therapy and lifestyle advice based on their diagnosis. The study also includes a registry for patients with obstructive disease who are not randomized. During the study, participants complete symptom questionnaires like the Seattle Angina Questionnaire to assess their angina symptoms and quality of life over at least 12 months. Researchers monitor health status, clinical outcomes, safety, and health economics, with ongoing follow-up planned for up to 10 years. Both patients and their usual care clinicians are blinded to the group allocation, but informed about the diagnosis to guide treatment. The trial aims to enroll 1500 participants across multiple centers in Europe, assessing the feasibility and impact of this stratified medicine approach.
1-10 of 23
1